Goldman Sachs’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $102M | Sell |
323,245
-57,866
| -15% | -$13.6M | 0.01% | 1210 |
|
|
2026
Q1 | $76.1M | Sell |
381,111
-47,893
| -11% | -$9.48M | 0.01% | 1237 |
|
|
2025
Q4 | $81.1M | Buy |
429,004
+61,209
| +17% | +$11.8M | 0.01% | 1140 |
|
|
2025
Q3 | $65.2M | Buy |
367,795
+304,073
| +477% | +$45.2M | 0.01% | 1232 |
|
|
2025
Q2 | $7.24M | Sell |
63,722
-21,133
| -25% | -$2.26M | ﹤0.01% | 3067 |
|
|
2025
Q1 | $8.92M | Sell |
84,855
-25,754
| -23% | -$2.91M | ﹤0.01% | 2800 |
|
|
2024
Q4 | $11.9M | Buy |
110,609
+15,356
| +16% | +$1.74M | ﹤0.01% | 2627 |
|
|
2024
Q3 | $9.53M | Buy |
95,253
+30,656
| +47% | +$3.09M | ﹤0.01% | 2780 |
|
|
2024
Q2 | $5.44M | Buy |
64,597
+7,486
| +13% | +$596K | ﹤0.01% | 3069 |
|
|
2024
Q1 | $4.17M | Sell |
57,111
-6,765
| -11% | -$499K | ﹤0.01% | 3266 |
|
|
2023
Q4 | $4.56M | Sell |
63,876
-5,965
| -9% | -$352K | ﹤0.01% | 3243 |
|
|
2023
Q3 | $4.18M | Sell |
69,841
-36,953
| -35% | -$2.43M | ﹤0.01% | 3143 |
|
|
2023
Q2 | $7.7M | Buy |
106,794
+44,803
| +72% | +$3.36M | ﹤0.01% | 2703 |
|
|
2023
Q1 | $4.56M | Buy |
61,991
+246
| +0.4% | +$17.5K | ﹤0.01% | 3151 |
|
|
2022
Q4 | $4.12M | Buy |
61,745
+4,425
| +8% | +$288K | ﹤0.01% | 3340 |
|
|
2022
Q3 | $3.08M | Sell |
57,320
-12,484
| -18% | -$734K | ﹤0.01% | 3580 |
|
|
2022
Q2 | $3.88M | Sell |
69,804
-16,532
| -19% | -$938K | ﹤0.01% | 3402 |
|
|
2022
Q1 | $6.06M | Sell |
86,336
-54,529
| -39% | -$3.96M | ﹤0.01% | 3176 |
|
|
2021
Q4 | $13.6M | Buy |
140,865
+44,113
| +46% | +$4.08M | ﹤0.01% | 2486 |
|
|
2021
Q3 | $8.41M | Sell |
96,752
-60,079
| -38% | -$4.65M | ﹤0.01% | 2886 |
|
|
2021
Q2 | $12.8M | Sell |
156,831
-57,764
| -27% | -$4.8M | ﹤0.01% | 2458 |
|
|
2021
Q1 | $20.4M | Sell |
214,595
-216,109
| -50% | -$20.4M | 0.01% | 1915 |
|
|
2020
Q4 | $26.7M | Buy |
430,704
+264,739
| +160% | +$15.1M | 0.01% | 1618 |
|
|
2020
Q3 | $9.87M | Sell |
165,965
-15,214
| -8% | -$1.04M | ﹤0.01% | 2336 |
|
|
2020
Q2 | $12.6M | Sell |
181,179
-6,981
| -4% | -$443K | ﹤0.01% | 2081 |
|
|
2020
Q1 | $8.54M | Sell |
188,160
-28,250
| -13% | -$1.6M | ﹤0.01% | 2199 |
|
|
2019
Q4 | $14.1M | Buy |
216,410
+55,544
| +35% | +$3.71M | ﹤0.01% | 2162 |
|
|
2019
Q3 | $9.99M | Sell |
160,866
-326,497
| -67% | -$20.5M | ﹤0.01% | 2329 |
|
|
2019
Q2 | $34.7M | Sell |
487,363
-115,910
| -19% | -$8.54M | 0.01% | 1415 |
|
|
2019
Q1 | $47.3M | Buy |
603,273
+121,334
| +25% | +$9.19M | 0.01% | 1167 |
|
|
2018
Q4 | $40.8M | Buy |
481,939
+122,721
| +34% | +$13.1M | 0.01% | 1239 |
|
|
2018
Q3 | $61.5M | Sell |
359,218
-231,699
| -39% | -$34.9M | 0.02% | 1077 |
|
|
2018
Q2 | $76.4M | Buy |
590,917
+163,937
| +38% | +$18.3M | 0.02% | 921 |
|
|
2018
Q1 | $44M | Buy |
426,980
+71,526
| +20% | +$7.07M | 0.01% | 1286 |
|
|
2017
Q4 | $30.4M | Sell |
355,454
-70,436
| -17% | -$6.11M | 0.01% | 1632 |
|
|
2017
Q3 | $36.2M | Sell |
425,890
-14,215
| -3% | -$1.13M | 0.01% | 1518 |
|
|
2017
Q2 | $33.3M | Buy |
440,105
+52,504
| +14% | +$3.67M | 0.01% | 1546 |
|
|
2017
Q1 | $25.6M | Buy |
387,601
+116,402
| +43% | +$7.66M | 0.01% | 1722 |
|
|
2016
Q4 | $17.2M | Sell |
271,199
-81,952
| -23% | -$5.17M | ﹤0.01% | 2068 |
|
|
2016
Q3 | $22.5M | Buy |
353,151
+303,476
| +611% | +$22.3M | 0.01% | 1804 |
|
|
2016
Q2 | $3.7M | Buy |
49,675
+14,454
| +41% | +$1.07M | ﹤0.01% | 3109 |
|
|
2016
Q1 | $2.35M | Buy |
35,221
+20,783
| +144% | +$1.26M | ﹤0.01% | 3331 |
|
|
2015
Q4 | $977K | Sell |
14,438
-45,851
| -76% | -$2.83M | ﹤0.01% | 4325 |
|
|
2015
Q3 | $3.22M | Sell |
60,289
-87,565
| -59% | -$5.31M | ﹤0.01% | 3307 |
|
|
2015
Q2 | $9.31M | Sell |
147,854
-442,007
| -75% | -$24.1M | ﹤0.01% | 2381 |
|
|
2015
Q1 | $28.4M | Buy |
589,861
+258,000
| +78% | +$9.88M | 0.01% | 1514 |
|
|
2014
Q4 | $11M | Sell |
331,861
-12,843
| -4% | -$418K | ﹤0.01% | 2271 |
|
|
2014
Q3 | $10.1M | Buy |
344,704
+21,985
| +7% | +$730K | ﹤0.01% | 2356 |
|
|
2014
Q2 | $12.5M | Buy |
322,719
+119,326
| +59% | +$4.84M | ﹤0.01% | 2196 |
|
|
2014
Q1 | $8.54M | Sell |
203,393
-44,944
| -18% | -$1.87M | ﹤0.01% | 2507 |
|
|
2013
Q4 | $8.15M | Buy |
248,337
+123,279
| +99% | +$4.02M | ﹤0.01% | 2555 |
|
|
2013
Q3 | $3.38M | Buy |
125,058
+15,041
| +14% | +$423K | ﹤0.01% | 3373 |
|
|
2013
Q2 | $2.57M | Buy |
+110,017
| New | +$1.98M | ﹤0.01% | 3458 |
|
Other funds holding LGND
JT
CAM
Goldman Sachs's LGND Position: Q2 2026 in Review
Goldman Sachs reduced its Ligand Pharmaceuticals (LGND) stake by 15% in Q2 2026, selling an estimated $13.6M and leaving 323,245 shares worth $102M. The position accounts for 0.01% of the portfolio, ranked #1210.
Goldman Sachs first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Goldman Sachs held 323,245 shares of Ligand Pharmaceuticals worth $102M as of Q2 2026.
- Goldman Sachs sold 57,866 Ligand Pharmaceuticals shares in Q2 2026, an estimated $13.6M.
- Ligand Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1210 holding.
- Goldman Sachs first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.